Fierce Biotech April 11, 2024
Researchers have demonstrated that a functional precision medicine approach—combining artificial intelligence, DNA sequencing, mutation mapping and drug sensitivity testing—could feasibly help tackle hard-to-treat cancers regardless of their type, including among children with relapsed solid tumors and blood-based malignancies.
The process, being developed by First Ascent Biomedical, showed promise in a small study published this week in Nature Medicine. It begins by collecting, culturing and analyzing tumor cells from each individual patient and then exposing those samples to more than 10 dozen FDA-approved drugs, including some that are aimed at cancer and some that are not, such as statins for high cholesterol.
Picking out the best performers and potential combinations takes about a week. Out of six patients who received these...
Today's Sponsors
Today's Sponsor